Pfizer/Aventis File For Exubera In Europe; No Timeline Yet On U.S. Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
With extensive use of inhaled insulin expected "right out of the box," the development partners are focused on getting Exubera through, not to, regulatory agencies as quickly as possible, Pfizer CFO Shedlarz says.
You may also be interested in...
Exubera Inhaled Insulin Gets Favorable Committee Review In Europe
European Medicines Agency's Committee for Medicinal Products for Human Use recommends approval of Pfizer/Sanofi's agent for type 1 and 2 diabetes with post-market monitoring for pulmonary function decline and hypoglycemia.
Exubera Inhaled Insulin Gets Favorable Committee Review In Europe
European Medicines Agency's Committee for Medicinal Products for Human Use recommends approval of Pfizer/Sanofi's agent for type 1 and 2 diabetes with post-market monitoring for pulmonary function decline and hypoglycemia.
Exubera Inhaled Insulin User Fee Deadline Is January 2006
Pfizer and Sanofi-Aventis filed the Exubera NDA March 1; an early 2006 approval is based on a standard 10-month review. The companies expected to submit an NDA in 2001, but were delayed by pulmonary safety questions.